Patients with melanoma who switched from anti-CTLA-4 to anti-PD-(L)1 had an overall irAE rate of 37%, the majority (56%) of which were grade ≥ 3, but only 2 irAEs were recurring (3%; arthritis and colitis); this low recurrence rate is unique among the summarized studies [30]. Here, CTLA4 is linked to melanoma.